Navigation Links
Atossa Genetics to Present at the Second Annual Marcum LLP MicroCap Conference
Date:5/17/2013

SEATTLE, May 17, 2013 /PRNewswire/ -- Atossa Genetics, Inc. (NASDAQ: ATOS), The Breast Health Company™, announced today that Kyle Guse , Chief Financial Officer & General Counsel, will present at the Second Annual Marcum LLP MicroCap Conference on Thursday, May 30, 2013, in New York City at the Grand Hyatt Hotel.

The Company's presentation is scheduled to begin at 3:30 p.m. EDT and will be available via a live webcast. To access the webcast, go to www.atossagenetics.com.

For more information and registration, please visit the conference website: http://www.marcumllp.com/microcap.

About Atossa Genetics, Inc.

Atossa Genetics, Inc. (NASDAQ: ATOS; www.atossagenetics.com), The Breast Health Company™, is based in Seattle, WA, and is focused on preventing breast cancer through the commercialization of patented diagnostic medical devices and patented laboratory developed tests that can detect precursors to breast cancer up to eight years before mammography, and through research and development that will permit it to commercialize treatments for pre-cancerous lesions.

The National Reference Laboratory for Breast Health (NRLBH), a wholly owned subsidiary of Atossa Genetics, Inc., is a CLIA-certified high-complexity molecular diagnostic laboratory located in Seattle, WA.  The NRLBH provides the patented ForeCYTE Breast Health Test, a risk assessment test for women 18 to 73 years of age akin to the Pap Smear, and the ArgusCYTE Breast Health Test, a blood test for recurrence in breast cancer survivors that provides a "liquid biopsy" for circulating breast cancer cells and a tailored treatment plan for patients and their caregivers.

Forward-Looking Statements

Forward-looking statements in this press release are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the risks and uncertainties associated with actions by the FDA, regulatory clearances, responses to regulatory matters, Atossa's ability to continue to manufacture and sell its products, the efficacy of Atossa's products and services, the market demand for and acceptance of Atossa's products and services, performance of distributors and other risks detailed from time to time in Atossa's filings with the Securities and Exchange Commission, including without limitation its registration statement on Form S-1 filed April 5, 2013, and periodic reports on Form 10-K and 10-Q, each as amended and supplemented from time to time.

About Marcum LLP

Marcum LLP is one of the largest independent public accounting and advisory services firms in the nation. Ranked among the top 15, Marcum LLP offers the resources of 1,000 professionals, including over 125 partners, in more than 20 offices throughout New York, New Jersey, Massachusetts, Connecticut, Pennsylvania, California, Florida, Grand Cayman and China. Headquartered in New York City, the Firm's presence runs deep with full-service offices strategically located in major business markets. Marcum is a member of the Marcum Group, an organization providing a comprehensive range of professional services spanning accounting and advisory, technology solutions, wealth management, and executive and professional recruiting. The Marcum Group companies include Marcum LLP; Marcum Technology LLC; Marcum Search LLC; Marcum Financial Services LLC; Marcum Bernstein & Pinchuk LLP; MarcumBuchanan Associates LLC; and Marcum Cronus Partners LLC.

Investor or Corporate Contacts:

Atossa Genetics, Inc.
Kyle Guse
(800) 351-3902
Kyle.Guse@atossagenetics.com

Matthew D. Haines
MBS Value Partners
(212) 710-9686
Matt.Haines@mbsvalue.com


'/>"/>
SOURCE Marcum LLP
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Millennium HealthCare Signs Distribution Agreement with Atossa Genetics
2. Metamark Genetics Board of Directors Appoints Shawn M. Marcell President and Chief Executive Officer
3. NewLink Genetics to Present at the Needham and Company 12th Annual Healthcare Conference
4. NewLink Genetics Presents Preclinical Data on NLG919, a New Drug Candidate from a Novel Class of IDO Pathway Inhibitors for the Treatment of Cancer
5. NewLink Genetics Announces Timing of Fourth Quarter and Year-End 2012 Financial Results Conference Call
6. NewLink Genetics Corporation Announces Exercise of Underwriters Option and Closing of Public Offering of Common Stock
7. NewLink Genetics Corporation Announces Pricing of Public Offering of Common Stock
8. NewLink Genetics Corporation Announces Proposed Public Offering of Common Stock
9. Epigenetics Technology Market (Epigenomics, DNA Methylation, Histone Modifications, RNA Interference, Cancer Therapeutics, Personalized Medicine) (2012 - 2017)
10. Clinical Data from NewLink Genetics HyperAcute Prostate Cancer Immunotherapy Published in Journal of Immunotherapy
11. Amgen to Acquire deCODE Genetics, a Global Leader in Human Genetics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/17/2019)... (PRWEB) , ... July 16, ... ... industry-leading resource for finding quality assisted living options, has announced the Best ... facilities based on healthcare services, amenities, resident satisfaction, affordability and more.     , ...
(Date:7/17/2019)... Ariz. (PRWEB) , ... July 17, 2019 , ... ... right educational program. Based in a sunny city southeast of Phoenix, Unitek EMT ... needs. This accelerated program allows aspiring EMTs to pursue their dream careers without ...
(Date:7/13/2019)... ... July 12, 2019 , ... Autism is ... socialize with others. Given how widespread autism is (approximately 1 in 59 people ... cannot be “cured,” there are treatment options to teach children with autism methods ...
Breaking Medicine Technology:
(Date:7/13/2019)... ... July 12, 2019 , ... ... launch of its proprietary patient management platform, Ospitek “View”. Ospitek has partnered with ... to deliver a fully customizable, intelligent, solution made specifically for surgical centers, allowing ...
(Date:7/13/2019)... ... July 12, 2019 , ... ... CUBIO Innovation Center , sponsored by Hangzhou Investment Promotion Bureau, Fox Rothschild LLP, ... 2019. , The conference attracted Fosun Pharmaceuticals, WuXi Biologics, Kelun Pharmaceutical, Harbin Pharmaceuticals, ...
(Date:7/12/2019)... NEW YORK (PRWEB) , ... July 12, 2019 ... ... that the company has gained Full Recognition status for its diabetes prevention program ... the first Diabetes Prevention Program (DPP) provider to gain full recognition from CDC ...
(Date:7/11/2019)... ... July 11, 2019 , ... Swagelok Southeast ... of its territory through the acquisition of another Houston-area distributor. The acquisition of ... three facilities located in LaPorte, Nederland and Houston. , With this expansion, ...
(Date:7/11/2019)... ... 11, 2019 , ... The Grain Chain, a farm to ... American Bakers Association (ABA), testified today on the nutritional benefits of bread and ... the Committee’s scientific report, due next year, will form the basis of the ...
Breaking Medicine News(10 mins):